In a recent study, Ma and collaborators demonstrated that PKC-β overexpression was associated with resistance to TKIs and its inhibition in CML CD34+ cells increased the sensitivity to Imatinib [115]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.